Viracta Therapeutics has a quick ratio of 1.35. It generally indicates good short-term financial strength.
The historical rank and industry rank for Viracta Therapeutics's Quick Ratio or its related term are showing as below:
VIRX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.35 Med: 8.93 Max: 21.12
Current: 1.35
During the past 4 years, Viracta Therapeutics's highest Quick Ratio was 21.12. The lowest was 1.35. And the median was 8.93.
VIRX's Quick Ratio is ranked worse than 74.98% of 1551
companies
in the Biotechnology industry
Industry Median: 3.53
vs VIRX: 1.35
Viracta Therapeutics Quick Ratio Historical Data
The historical data trend for Viracta Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viracta Therapeutics's Quick Ratio
For the Biotechnology subindustry, Viracta Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's Quick Ratio falls into.
Viracta Therapeutics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Viracta Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viracta Therapeutics (NAS:VIRX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Viracta Therapeutics Quick Ratio Related Terms
Thank you for viewing the detailed overview of Viracta Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Viracta Therapeutics (Viracta Therapeutics) Business Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIRX has been successfully added to your 